论文部分内容阅读
目的研究PI3-K抑制剂LY294002在大鼠体内应用时对膀胱灌注化疗药物丝裂霉素C(mitomycin C,MMC)的协同抑癌作用以及毒副作用。方法对荷原位膀胱癌的大鼠进行膀胱内灌注生理盐水、MMC、LY294002,记录大鼠体重变化、CT动态观察膀胱肿瘤变化、处死后直接测量膀胱肿瘤大小及观察灌注治疗完成后的存活率。结果 MMC联合LY294002灌注治疗4周后,荷膀胱癌大鼠平均体重明显高于单独MMC治疗组,CT扫描显示MMC联合LY294002灌注治疗对膀胱肿瘤的抑制作用强于单独MMC灌注。MMC联合LY294002灌注治疗4周后,大鼠膀胱内肿瘤直径小于单独MMC灌注组。灌注治疗4周后,各组大鼠存活率差异无统计学意义。LY294002灌注治疗会导致大鼠一过性的体重下降,无其他严重不良反应发生。结论 LY294002能增强MMC对大鼠膀胱癌的抑制作用,LY294002在大鼠体内应用时无严重不良反应发生。
Objective To study the synergistic anti-tumor effect and side effect of intravesical chemotherapy of mitomycin C (MMC) on PI3-K inhibitor LY294002 in rats. Methods The rats with bladder cancer in situ were infused with saline, MMC and LY294002 intraperitoneally to record the change of body weight in rats. CT dynamic changes of bladder tumor were observed. The size of bladder tumor was measured directly after death and the survival rate after completion of perfusion was observed . Results After 4 weeks of MMC combined with LY294002 perfusion, the average body weight of bladder cancer-bearing rats was significantly higher than that of MMC alone. The CT scan showed that MMC combined with LY294002 perfusion therapy had a better inhibitory effect on bladder cancer than MMC alone. MMC combined with LY294002 perfusion treatment for 4 weeks, the diameter of the bladder tumor in rats smaller than MMC alone group. After 4 weeks of perfusion treatment, there was no significant difference in the survival rate of rats in each group. LY294002 infusion therapy will lead to transient weight loss in rats, no other serious adverse reactions. Conclusion LY294002 can enhance the inhibitory effect of MMC on bladder cancer in rats. LY294002 has no serious side effects when used in rats.